{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:27:02Z","timestamp":1787063222420,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA035772"],"award-info":[{"award-number":["P30DA035772"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM987654"],"award-info":[{"award-number":["R01GM987654"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1DA049412"],"award-info":[{"award-number":["UM1DA049412"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCT04111939"],"award-info":[{"award-number":["NCT04111939"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.josat.2024.209441","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T13:21:43Z","timestamp":1718803303000},"page":"209441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application"],"prefix":"10.1016","volume":"165","author":[{"given":"Diana","family":"Bowser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot T.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hodgkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Horgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2024.209441_bb0005","author":"Ahmad"},{"issue":"3","key":"10.1016\/j.josat.2024.209441_bb0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2105\/AJPH.2018.304856","article-title":"Impact of Medicaid restrictions on availability of buprenorphine in addiction treatment programs","volume":"109","author":"Andrews","year":"2019","journal-title":"American Journal of Public Health"},{"issue":"8","key":"10.1016\/j.josat.2024.209441_bb0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2020.8969","article-title":"Therapies offered at residential addiction treatment programs in the United States","volume":"324","author":"Beetham","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.josat.2024.209441_bb0020","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1001\/jama.2022.6469","article-title":"From scientific discovery to covered treatments: Understanding the payer perspective as a keystone to achieving high-value care","volume":"327","author":"Blanco","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2024.209441_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2022.100126","article-title":"The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses","volume":"6","author":"Bohler","year":"2023","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2024.209441_bb0030","author":"Bowser"},{"issue":"6","key":"10.1016\/j.josat.2024.209441_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14925","article-title":"Estimated reductions in opioid overdose deaths with sustainment of public health interventions in 4 US states","volume":"6","author":"Chhatwal","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209441_bb0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: Motives for abuse, misuse, and diversion","volume":"104","author":"Chilcoat","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2024.209441_bb0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.josat.2024.209441_bb0050","first-page":"1964","article-title":"The impact of prior authorization on buprenorphine dose, relapse rates, and cost for Massachusetts Medicaid beneficiaries with opioid dependence","volume":"49","author":"Clark","year":"2014","journal-title":"Health Services Research"},{"issue":"1","key":"10.1016\/j.josat.2024.209441_bb0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13011-022-00478-y","article-title":"Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by medicare in 2021","volume":"17","author":"Clemans-Cope","year":"2022","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.josat.2024.209441_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209022","article-title":"The role of health plans in addressing the opioid crisis: A qualitative study","author":"Davis","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2024.209441_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.209022","article-title":"The role of health plans in addressing the opioid crisis: A qualitative study","volume":"149","author":"Davis","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2024.209441_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.josat.2024.209441_bb0075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.37765\/ajmc.2022.89250","article-title":"The impact of HDHPs on service use and spending for substance use disorders","volume":"28","author":"Eisenberg","year":"2022","journal-title":"The American Journal of Managed Care"},{"issue":"7","key":"10.1016\/j.josat.2024.209441_bb0080","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamapsychiatry.2021.0247","article-title":"Cost-effectiveness of treatments for opioid use disorder","volume":"78","author":"Fairley","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.josat.2024.209441_bb0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jgs.16281","article-title":"Help is on the way: Medicare coverage of opioid treatment programs","volume":"68","author":"Felix","year":"2020","journal-title":"Journal of the American Geriatrics Society"},{"issue":"6","key":"10.1016\/j.josat.2024.209441_bb0090","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1097\/ADM.0000000000001007","article-title":"Buprenorphine initiation in the era of high-potency synthetic opioids: A call for community-based participatory research to help learning health systems provide precision medicine for opioid use disorder","volume":"16","author":"Fiellin","year":"2022","journal-title":"Journal of Addiction Medicine"},{"issue":"7","key":"10.1016\/j.josat.2024.209441_bb0095","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1377\/hlthaff.2023.00148","article-title":"Changes in county-level access to medications for opioid use disorder after Medicare coverage of methadone treatment began","volume":"42","author":"Harris","year":"2023","journal-title":"Health Affairs"},{"issue":"1","key":"10.1016\/j.josat.2024.209441_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13722-021-00253-7","article-title":"Financial sustainability of payment models for office-based opioid treatment in outpatient clinics","volume":"16","author":"Hodgkin","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"issue":"4","key":"10.1016\/j.josat.2024.209441_bb0105","first-page":"149","article-title":"Financial sustainability of novel delivery models in behavioral health treatment","volume":"26","author":"Hodgkin","year":"2023","journal-title":"The Journal of Mental Health Policy and Economics"},{"issue":"6","key":"10.1016\/j.josat.2024.209441_bb0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ADM.0000000000000980","article-title":"Medicaid prescription cap policies: Another structural barrier to medication for opioid use disorder","volume":"16","author":"Hughto","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2024.209441_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.josat.2023.208980","article-title":"Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019","volume":"147","author":"Ijioma","year":"2023","journal-title":"Journal of Substance Use and Addiction Treatment"},{"key":"10.1016\/j.josat.2024.209441_bb0120","series-title":"Development of medications for the treatment of opiate and cocaine addictions","author":"Institute of Medicine","year":"1995"},{"issue":"7","key":"10.1016\/j.josat.2024.209441_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1016\/j.josat.2024.209441_bb0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","article-title":"Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: A scoping review","volume":"16","author":"Krawczyk","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2024.209441_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019","author":"Krawczyk","year":"2022","journal-title":"The International Journal on Drug Policy"},{"issue":"3","key":"10.1016\/j.josat.2024.209441_bb0140","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: Implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"The Lancet. Public Health"},{"issue":"3","key":"10.1016\/j.josat.2024.209441_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.josat.2024.209441_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2023.2826","article-title":"Buprenorphine out-of-pocket costs and discontinuation in privately insured adults with opioid use disorder","author":"Leech","year":"2023","journal-title":"JAMA Internal Medicine"},{"issue":"7","key":"10.1016\/j.josat.2024.209441_bb0155","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1176\/appi.ps.201900025","article-title":"The affordable care act and opioid agonist therapy for opioid use disorder","volume":"70","author":"Mojtabai","year":"2019","journal-title":"Psychiatric Services (Washington, D.C.)"},{"key":"10.1016\/j.josat.2024.209441_bb0160","doi-asserted-by":"crossref","DOI":"10.1097\/MLR.0000000000001689","article-title":"Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design","author":"Morgan","year":"2022","journal-title":"Medical Care"},{"key":"10.1016\/j.josat.2024.209441_bb0165","author":"National Academies of Sciences, Engineering, and Medicine"},{"issue":"5","key":"10.1016\/j.josat.2024.209441_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.josat.2024.209441_bb0175","author":"O'Grady"},{"key":"10.1016\/j.josat.2024.209441_bb0180","author":"Orgera"},{"issue":"3","key":"10.1016\/j.josat.2024.209441_bb0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ps.201900373","article-title":"Private coverage of methadone in outpatient treatment programs","volume":"71","author":"Polsky","year":"2020","journal-title":"Psychiatric Services (Washington, D.C.)"},{"issue":"4","key":"10.1016\/j.josat.2024.209441_bb0190","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1037\/adb0000090","article-title":"Predictors of patient retention in methadone maintenance treatment","volume":"29","author":"Proctor","year":"2015","journal-title":"Psychology of Addictive Behaviors: Journal of the Society of Psychologists in Addictive Behaviors"},{"key":"10.1016\/j.josat.2024.209441_bb0195","series-title":"Why not better and cheaper?: Healthcare and innovation","author":"Rebitzer","year":"2023"},{"issue":"2","key":"10.1016\/j.josat.2024.209441_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/02791072.2017.1300360","article-title":"Commercial health plan coverage of selected treatments for opioid use disorders from 2003 to 2014","volume":"49","author":"Reif","year":"2017","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.josat.2024.209441_bb0205","author":"Roberts"},{"issue":"2","key":"10.1016\/j.josat.2024.209441_bb0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2105\/AJPH.2021.306577","article-title":"Self-reported treatment need and barriers to care for adults with opioid use disorder: The US National Survey on Drug Use and Health, 2015 to 2019","volume":"112","author":"Saini","year":"2022","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.josat.2024.209441_bb0215","author":"SAMHSA"},{"key":"10.1016\/j.josat.2024.209441_bb0220","author":"SAMHSA"},{"key":"10.1016\/j.josat.2024.209441_bb0225","author":"SAMHSA"},{"key":"10.1016\/j.josat.2024.209441_bb0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2024.209441_bb0235","author":"Schulman"},{"issue":"8","key":"10.1016\/j.josat.2024.209441_bb0240","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.2502","article-title":"Changes in Medicaid fee-for-service benefit design for substance use disorder treatment during the opioid crisis, 2014 to 2021","volume":"4","author":"Shoulders","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.josat.2024.209441_bb0245","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.54590","article-title":"Trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer, 2015 to 2020","volume":"6","author":"Strahan","year":"2023","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.josat.2024.209441_bb0250","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14328","article-title":"Trends in methadone dispensing for opioid use disorder after Medicare payment policy changes","volume":"6","author":"Taylor","year":"2023","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1016\/j.josat.2024.209441_bb0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.12030","article-title":"Buprenorphine utilization and prescribing among New Jersey Medicaid beneficiaries after adoption of initiatives designed to improve treatment access","volume":"6","author":"Treitler","year":"2023","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.josat.2024.209441_bb0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2024.209441_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108325","article-title":"The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study","volume":"217","author":"Winhusen","year":"2020","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592400153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294987592400153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:12:14Z","timestamp":1778937134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294987592400153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"alternative-id":["S294987592400153X"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2024.209441","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2024.209441","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209441"}}